From Investing.com: 2024-05-17 07:09:02

Doximity, Inc. (DOCS) exceeded Q4 revenue expectations, reaching $118 million and $475 million for fiscal year 2024. The company’s adjusted EBITDA margin was 48% with $56 million in earnings. Doximity introduced a $500 million share buyback program and projects Q1 2025 revenue between $119.5 million to $120.5 million, and $506 million to $518 million for the full fiscal year. With over 400,000 new healthcare professional registrations, the company’s network engagement has reached new heights. In response to market uncertainties, Doximity remains focused on growth and profitability through AI and new offerings, catering to Pharma brands and small to medium-sized healthcare businesses. CEO Jeff Tangney emphasized growth potential in the pharma segment and the company’s commitment to balancing expansion while ensuring value for shareholders. Analyst insights suggest Doximity’s financial strength and strategic positioning align with long-term growth prospects, supported by robust gross profit margins and a healthy balance sheet. To explore additional insights and analyses on Doximity’s performance, investors can visit the InvestingPro platform using the discount code PRONEWS24 for a discounted subscription.



Read more at Investing.com: Doximity tops Q4 guidance, plans $500M share buyback By Investing.com